VESELKA, Josef, David ZEMÁNEK, Denisa JAHNLOVÁ, Jan KREJČÍ, Jaroslav JANUŠKA, Maciej DABROWSKI, Thomas BARTEL and Pavol TOMAŠOV. Risk and Causes of Death in Patients After Alcohol Septal Ablation for Hypertrophic Obstructive Cardiomyopathy. Canadian Journal of Cardiology. New York: Elsevier Science Ltd., 2015, vol. 31, No 10, p. 1245-1251. ISSN 0828-282X. Available from: https://dx.doi.org/10.1016/j.cjca.2015.02.010.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Risk and Causes of Death in Patients After Alcohol Septal Ablation for Hypertrophic Obstructive Cardiomyopathy
Authors VESELKA, Josef (203 Czech Republic), David ZEMÁNEK (203 Czech Republic), Denisa JAHNLOVÁ (203 Czech Republic), Jan KREJČÍ (203 Czech Republic, guarantor, belonging to the institution), Jaroslav JANUŠKA (203 Czech Republic), Maciej DABROWSKI (616 Poland), Thomas BARTEL (784 United Arab Emirates) and Pavol TOMAŠOV (203 Czech Republic).
Edition Canadian Journal of Cardiology, New York, Elsevier Science Ltd. 2015, 0828-282X.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30201 Cardiac and Cardiovascular systems
Country of publisher United States of America
Confidentiality degree is not subject to a state or trade secret
Impact factor Impact factor: 3.112
RIV identification code RIV/00216224:14110/15:00085299
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.1016/j.cjca.2015.02.010
UT WoS 000365242300008
Keywords in English SUDDEN CARDIAC DEATH; LONG-TERM SURVIVAL; TASK-FORCE; MULTICENTER; PREVENTION; GUIDELINES; EXPERIENCE; DIAGNOSIS; MYECTOMY; THERAPY
Tags EL OK
Tags International impact, Reviewed
Changed by Changed by: Soňa Böhmová, učo 232884. Changed: 17/12/2015 11:34.
Abstract
Background: Because the final myocardial scar might be theoretically associated with an increased risk of sudden cardiac death, the longterm clinical course of patients who undergo alcohol septal ablation (ASA) is still a matter of debate. In this retrospective multicentre study, we report outcomes after ASA, including survival, analysis of causes of deaths, and association between time and cause of death. Methods: We enrolled 366 consecutive patients (58 +/- 12 years, 54% women) who were treated using ASA and followed-up for 5.1 +/- 4.5 years. Results: The in-hospital and 30-day mortality were 0.5% and 0.8%, respectively; the ASA-related morbidity was < 20%. Overall, 52 patients died during 1867 patient-years, which means the all-cause mortality rate was 2.8% per year. The mortality rates of sudden death and sudden death with an appropriate implantable cardioverterdefibrillator (ICD) discharge were 0.4% and 1% per year, respectively. Patients with sudden death or appropriate ICD discharge experienced these mortality events at younger age than patients who died of other hypertrophic obstructive cardiomyopathy-related causes (60.8 years [range, 52-71.5 years] vs 72.4 years [range, 64.2-75.2 years]; P = 0.048). A total of 292 patients (80%) had an outflow gradient <= 30 mm Hg, and 327 patients (89%) were in New York Heart Association class <= II at the last clinical check-up. Conclusions: ASA had low procedure-related mortality, with subsequent 1% occurrence of sudden mortality events per year and 2.8% mortality rate per year in the long-term follow-up. Patients with sudden death or ICD discharge experienced the mortality events approximately 1 decade earlier than patients who died from other causes not related to hypertrophic cardiomyopathy.
PrintDisplayed: 7/10/2024 04:18